Annovis Shares Rise After Study Shows Effectiveness of Parkinson's Treatment Candidate

MT Newswires Live07-03

Annovis Bio (ANVS) shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.

Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.

Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.

Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.

Price: 6.57, Change: +1.30, Percent Change: +24.67

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448504164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-03 00:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448504164","market":"sg","top_or_hot":-1,"title":"Annovis Shares Rise After Study Shows Effectiveness of Parkinson's Treatment Candidate","media":"MT Newswires Live","content":"<html><body><p> Annovis Bio (ANVS) shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.</p><p>Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.</p><p>Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.</p><p>Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.</p><p>Price: 6.57, Change: +1.30, Percent Change: +24.67</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Shares Rise After Study Shows Effectiveness of Parkinson's Treatment Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Shares Rise After Study Shows Effectiveness of Parkinson's Treatment Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-03 00:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Annovis Bio (ANVS) shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2448504164","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448504164","pubTimestamp":1719938621,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Annovis Bio  shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.Price: 6.57, Change: +1.30, Percent Change: +24.67","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","ANVS":"Annovis Bio, Inc."},"translate_title":"研究显示帕金森病候选治疗药物的有效性后，Annovis股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":0.9},"content_text":"Annovis Bio (ANVS) shares surged 25% in recent trading Tuesday after an advance study showed buntanetap was effective in improving motor, non-motor and cognitive functions in patients with early Parkinson's disease.Buntanetap halted cognitive decline in all enrolled patients, while patients with mild dementia showed improved cognition, the company said.Annovis said the drug showed improvement in motor and non-motor functions in patients diagnosed with Parkinson's disease more than three years and patients with postural instability and gait difficulty.Results from the study show that buntanetap met both primary and secondary endpoints in specified subgroups.Price: 6.57, Change: +1.30, Percent Change: +24.67","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448504164"}